5 May 2026 - Spinogenix today announced that the US FDA has granted fast track designation to tazbentetol for the treatment of people with amyotrophic lateral sclerosis.

Tazbentetol is a once a day pill being developed as a first-in-class, regenerative treatment with the potential to restore synapses, the key connections between neurons that allow people to think, plan, remember and control movement.

Read Spinogenix press release